Unique ID issued by UMIN | UMIN000012382 |
---|---|
Receipt number | R000014478 |
Scientific Title | Treatment protocol for adult acute lymphoblastic leukemia -ALL/MRD2014- |
Date of disclosure of the study information | 2014/01/01 |
Last modified on | 2021/11/29 14:10:33 |
Treatment protocol for adult acute lymphoblastic leukemia
-ALL/MRD2014-
ALL/MRD2014
Treatment protocol for adult acute lymphoblastic leukemia
-ALL/MRD2014-
ALL/MRD2014
Japan |
acute lymphoblastic leukemia
Hematology and clinical oncology |
Malignancy
NO
We plan the risk-adjusted treatment protocol for adult acute lymphocytic leukemia.
The risks are determined by the MRD status post consolidation treatment.
High-risk patients will proceed to allogeneic hematopoietic stem cell transplantation, while low-risk patients will proceed to maintenance treatment.
Efficacy
Confirmatory
Phase II
3 years disease-free survival
5 years disease-free survival, CR rate, treatment-related toxicities
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
In adult BCR/ABL negative ALL, the indication of allogeneic HSCT will be determined by the MRD status. High-risk patients will proceed to allogeneic HSCT. Low-risk patients will proceed to maintenance treatment which is less toxic than HSCT.
In adult BCR/ABL positive ALL, patients will receive induction therapy combined with dasatinib. Every patient will proceed to allogeneic HSCT whenever possible.
16 | years-old | <= |
65 | years-old | >= |
Male and Female
1. acute lymphoblastic leukemia by WHO classification
2. peroxidase positive rate of the blast cell, 3% are less than it
3. The first time treatment example which does not catch chemotherapy or the radiotherapy
4. The case that is equal to or less than 65 years old more than age 15 years old
5. Performance status 0-2
6. A case without the dangerously ill internal organs disorder
T.Bil equal to or less than 2.0mg/dL, Cr equal to or less than 2.0mg/dL
7. The case that an agreement by the document is provided from a patient on explanation because of final examination contents
1. B-ALL(L3) of the blast cell cell surface immune globulin positive
2. A case having double cancers
3. A case with an infectious disease having difficulty with control
4. A case with a severe mental disorder
5. The pregnancy or breast-feeding woman
6. the case that the medical attendant judged to be inappropriate
100
1st name | Koji Nagafuji / Yoshikiyo Ito |
Middle name | |
Last name | Koji Nagafuji / Yoshikiyo Ito |
Koji Nagafuji / Yoshikiyo Ito
Kurume University Hospital / Harasanshin Hospital
Division of Hematology and Oncology / Department of Hematology
8300011
67 Asahi-machi, Kurume 830-0011, Japan / 1-8 Taihakumachi, Hakata Ward, Fukuoka
0942-31-7852
knagafuji@med.kurume-u.ac.jp
1st name | The secretariat |
Middle name | |
Last name | The secretariat |
Fukuoka Blood & Marrow Transplant Group
Head office of FBMTG
8128582
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
092-642-5315
http://f-bmtg.jp/index.html
fbmtg@intmed1.med.kyushu-u.ac.jp
Fukuoka Blood & Marrow Transplant Group
Research Foundation for Community Medicine
Non profit foundation
Kurume University Medical Ethics Committee
67 Asahi-machi, Kurume 830-0011
0942-31-7917
i_rinri@kurume-u.ac.jp
NO
2014 | Year | 01 | Month | 01 | Day |
Unpublished
No longer recruiting
2013 | Year | 11 | Month | 22 | Day |
2014 | Year | 01 | Month | 15 | Day |
2014 | Year | 02 | Month | 16 | Day |
2022 | Year | 12 | Month | 31 | Day |
2013 | Year | 11 | Month | 22 | Day |
2021 | Year | 11 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014478